231 related articles for article (PubMed ID: 26282717)
1. The sGC stimulator riociguat inhibits platelet function in washed platelets but not in whole blood.
Reiss C; Mindukshev I; Bischoff V; Subramanian H; Kehrer L; Friebe A; Stasch JP; Gambaryan S; Walter U
Br J Pharmacol; 2015 Nov; 172(21):5199-210. PubMed ID: 26282717
[TBL] [Abstract][Full Text] [Related]
2. Activation of haem-oxidized soluble guanylyl cyclase with BAY 60-2770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway.
Mendes-Silverio CB; Leiria LO; Morganti RP; Anhê GF; Marcondes S; Mónica FZ; De Nucci G; Antunes E
PLoS One; 2012; 7(11):e47223. PubMed ID: 23144808
[TBL] [Abstract][Full Text] [Related]
3. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats.
Lang M; Kojonazarov B; Tian X; Kalymbetov A; Weissmann N; Grimminger F; Kretschmer A; Stasch JP; Seeger W; Ghofrani HA; Schermuly RT
PLoS One; 2012; 7(8):e43433. PubMed ID: 22912874
[TBL] [Abstract][Full Text] [Related]
4. Soluble guanylate cyclase stimulators in pulmonary hypertension.
Stasch JP; Evgenov OV
Handb Exp Pharmacol; 2013; 218():279-313. PubMed ID: 24092345
[TBL] [Abstract][Full Text] [Related]
5. The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats.
Reinke Y; Gross S; Eckerle LG; Hertrich I; Busch M; Busch R; Riad A; Rauch BH; Stasch JP; Dörr M; Felix SB
Eur J Pharmacol; 2015 Nov; 767():1-9. PubMed ID: 26407652
[TBL] [Abstract][Full Text] [Related]
6. cAMP- and cGMP-elevating agents inhibit GPIbα-mediated aggregation but not GPIbα-stimulated Syk activation in human platelets.
Makhoul S; Trabold K; Gambaryan S; Tenzer S; Pillitteri D; Walter U; Jurk K
Cell Commun Signal; 2019 Sep; 17(1):122. PubMed ID: 31519182
[TBL] [Abstract][Full Text] [Related]
7. Riociguat for the treatment of pulmonary hypertension.
Hambly N; Granton J
Expert Rev Respir Med; 2015; 9(6):679-95. PubMed ID: 26599488
[TBL] [Abstract][Full Text] [Related]
8. Biphasic roles for soluble guanylyl cyclase (sGC) in platelet activation.
Zhang G; Xiang B; Dong A; Skoda RC; Daugherty A; Smyth SS; Du X; Li Z
Blood; 2011 Sep; 118(13):3670-9. PubMed ID: 21803853
[TBL] [Abstract][Full Text] [Related]
9. The chemistry and biology of soluble guanylate cyclase stimulators and activators.
Follmann M; Griebenow N; Hahn MG; Hartung I; Mais FJ; Mittendorf J; Schäfer M; Schirok H; Stasch JP; Stoll F; Straub A
Angew Chem Int Ed Engl; 2013 Sep; 52(36):9442-62. PubMed ID: 23963798
[TBL] [Abstract][Full Text] [Related]
10. Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Dasgupta A; Bowman L; D'Arsigny CL; Archer SL
Clin Pharmacol Ther; 2015 Jan; 97(1):88-102. PubMed ID: 25670386
[TBL] [Abstract][Full Text] [Related]
11. Analysis of nitric oxide-sensitive guanylyl cyclase in human platelets before and after aggregation.
Kempfert J; Behrends S
Platelets; 2003; 14(7-8):429-35. PubMed ID: 14713512
[TBL] [Abstract][Full Text] [Related]
12. Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
Lian TY; Jiang X; Jing ZC
Drug Des Devel Ther; 2017; 11():1195-1207. PubMed ID: 28458514
[TBL] [Abstract][Full Text] [Related]
13. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
Boerrigter G; Burnett JC
Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
[TBL] [Abstract][Full Text] [Related]
14. Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockade.
Ott IM; Alter ML; von Websky K; Kretschmer A; Tsuprykov O; Sharkovska Y; Krause-Relle K; Raila J; Henze A; Stasch JP; Hocher B
PLoS One; 2012; 7(8):e42623. PubMed ID: 22900035
[TBL] [Abstract][Full Text] [Related]
15. Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats.
Geschka S; Kretschmer A; Sharkovska Y; Evgenov OV; Lawrenz B; Hucke A; Hocher B; Stasch JP
PLoS One; 2011; 6(7):e21853. PubMed ID: 21789188
[TBL] [Abstract][Full Text] [Related]
16. Soluble guanylate cyclase stimulator riociguat improves spatial memory in mice via peripheral mechanisms.
Nelissen E; van Hagen BTJ; Argyrousi EK; van Goethem NP; Heckman PRA; Paes D; Mulder-Jongen DAJ; Ramaekers JG; Blokland A; Schmidt HHHW; Prickaerts J
Neurosci Lett; 2022 Sep; 788():136840. PubMed ID: 35985509
[TBL] [Abstract][Full Text] [Related]
17. Effects of the NO/soluble guanylate cyclase/cGMP system on the functions of human platelets.
Makhoul S; Walter E; Pagel O; Walter U; Sickmann A; Gambaryan S; Smolenski A; Zahedi RP; Jurk K
Nitric Oxide; 2018 Jun; 76():71-80. PubMed ID: 29550521
[TBL] [Abstract][Full Text] [Related]
18. Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signalling.
Beyer C; Zenzmaier C; Palumbo-Zerr K; Mancuso R; Distler A; Dees C; Zerr P; Huang J; Maier C; Pachowsky ML; Friebe A; Sandner P; Distler O; Schett G; Berger P; Distler JH
Ann Rheum Dis; 2015 Jul; 74(7):1408-16. PubMed ID: 24567525
[TBL] [Abstract][Full Text] [Related]
19. The anti-aggregating effect of BAY 41-2272, a stimulator of soluble guanylyl cyclase, requires the presence of nitric oxide.
Roger S; Badier-Commander C; Paysant J; Cordi A; Verbeuren TJ; Félétou M
Br J Pharmacol; 2010 Nov; 161(5):1044-58. PubMed ID: 20977455
[TBL] [Abstract][Full Text] [Related]
20. The effects of the soluble guanylate cyclase stimulator riociguat on memory performance in healthy volunteers with a biperiden-induced memory impairment.
Borghans LGJM; Sambeth A; Prickaerts J; Ramaekers JG; Blokland A
Psychopharmacology (Berl); 2018 Aug; 235(8):2407-2416. PubMed ID: 29882087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
